Stoke Therapeutics, Inc. — Director's Dealing 2021

Feb 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2021-02-19

Reporting Person: TZIANABOS ARTHUR (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-19	Common Stock	M	10000	$2.19	Acquired	10000	Direct
2021-02-19	Common Stock	S	10000	$60.6652	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-19	Director Stock Option (Right to Buy)	$2.19	M	10000	Disposed	2028-12-12	Common Stock (10000)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The option vested as to 1/48th of the total shares on October 4, 2018 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.